SCHEMBL4604248

SCHEMBL4604248

CCC(=O)Nc1ccc(O)cc1C(=O)OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.57
CA1 P00915 3/20 0.57
CA2 P00918 3/20 0.57
CA7 P43166 3/20 0.57
CA9 Q16790 3/20 0.57
CA14 Q9ULX7 3/20 0.57
PDK2 Q15119 1/20 0.53
PDK4 Q16654 1/20 0.53
KMT2A Q03164 2/20 0.53
HTT P42858 2/20 0.53
ALDH1A1 P00352 9/20 0.49
KDM4E B2RXH2 7/20 0.49
LMNA P02545 1/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 6/20 0.48
MAPT P10636 1/20 0.46
HSP90AB1 P08238 1/20 0.45
TSHR P16473 1/20 0.44
MAPK10 P53779 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28942209 0.86 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL4605157 0.86 L3MBTL1 (0.55) KMT2AHTTALDH1A1KDM4ELMNA
SCHEMBL1826550 0.84 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL4605989 0.84 GAA (0.51) KMT2AHTTALDH1A1KDM4ELMNA
SCHEMBL22650326 0.84 HTT (0.50) KMT2AHTTALDH1A1KDM4ELMNA
SCHEMBL29441245 0.84 ALDH1A1 (0.60) KMT2AHTTALDH1A1KDM4ELMNA
SCHEMBL4604562 0.84 ALDH1A1 (0.60) KMT2AHTTALDH1A1KDM4ELMNA
SCHEMBL5317664 0.82 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL1826967 0.82 HTT (0.48) KMT2AHTTALDH1A1KDM4ELMNA
SCHEMBL1025962 0.81 CA12 (0.62) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 CA12 1087/4885CA1 1750/4885CA2 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.